**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously presented) A quinazoline derivative of the Formula (I):



(I)

wherein:

either $R^2$ is in the 6-position and the substituted-pyrrolidinyloxy group is in the 7-position of the quinazoline ring or $R^2$ is in the 7-position and the substituted-pyrrolidinyloxy group is in the 6-position of the quinazoline ring;

A is phenyl or pyridyl;

each $R^1$ is a substituent on a ring carbon atom in ring A and is independently selected from halogeno, cyano, nitro, hydroxy, carboxy, trifluoromethyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkoxycarbonyl, ureido, N-(1-6C)alkylureido, N,N-di-[(1-6C)alkyl]ureido, $-NR^aR^b$, $-SO_2NR^aR^b$ and a group of formula $-CONR^aR^b$ wherein $R^a$ is hydrogen or (1-6C)alkyl and $R^b$ selected from hydrogen, (1-6C)alkyl, phenyl, benzyl, heterocyclyl, heterocyclyl(1-3C)alkyl, heteroaryl, heteroaryl(1-

3C)alkyl, (3-7)cycloalkyl and (3-7)cycloalkyl(1-3C)alkyl wherein any alkyl, heterocyclyl, heteroaryl and cycloalkyl groups in $R^a$ and $R^b$ are optionally substituted by 1, 2 or 3 substituents selected from (1-4C)alkyl, halogeno, hydroxy and (1-4C)alkoxy;

or $R^a$ and $R^b$ together with the nitrogen atom to which they are attached form a 4, 5 or 6-membered ring which optionally contains an additional ring heteroatom selected from nitrogen, oxygen and sulphur and which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy and optionally substituted on any available ring nitrogen by a substituent selected from (1-4C)alkyl and (2-4C)alkanoyl provided the ring is not thereby quaternised,

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by $R^a$ and $R^b$ together with the nitrogen atom to which they are attached is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno, hydroxyl, (1-4C)alkyl and (1-4C)alkoxy;

or, when two $R^1$ groups are attached to adjacent carbon atoms, they may, together with the carbon atoms to which they are attached, form a pyrrole ring, wherein the pyrrole ring is optionally substituted by 1 or 2 substituents independently selected from (1-6C)alkyl, halogeno, cyano, nitro, hydroxy, amino, carbamoyl, sulfamoyl and trifluoromethyl; or, when two $R^1$ groups are attached to adjacent carbon atoms, they may, together form a (1-3C)alkylenedioxy group [$-O(CH_2)_{1-3}O$];

m is 0, 1, 2 or 3;

each $R^2$ is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-3C)alkyl and a group of the formula $R^7O$-, wherein $R^7$ is (1-6C)alkyl

optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy and a group of the formula $R^8O$- wherein $R^8$ is (1-3C)alkyl;

$R^3$ is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-3C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (2-6C)alkanoyl, carbamoyl(1-6C)alkyl, N-(1-6C)alkylcarbamoyl(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl(1-6C)alkyl, sulfamoyl(1-6C)alkyl, N-(1-6C)alkylsulfamoyl(1-6C)alkyl, N,N-di-[(1-6C)alkyl]sulfamoyl(1-6C)alkyl and (2-6C)alkanoyl(1-6C)alkyl,

and wherein any (1-6C)alkyl or (2-6C)alkanoyl group within $R^3$ is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno, hydroxy and (1-6C)alkyl and/or optionally a substituent selected from cyano, nitro, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy and $NR^cR^d$, wherein $R^c$ is hydrogen or (1-4C)alkyl and $R^d$ is hydrogen or (1-4C)alkyl and wherein any (1-4C)alkyl in $R^c$ or $R^d$ is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno and hydroxy and/or optionally a substituent selected from cyano, nitro and (1-4C)alkoxy,

or $R^c$ and $R^d$ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which optionally contains an additional ring heteroatom selected from nitrogen, oxygen and sulphur and which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy, and optionally substituted on any available ring nitrogen by a substituent selected from (1-4C)alkyl and (2-4C)alkanoyl provided the ring is not thereby quaternised,

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by $R^c$ and $R^d$ together with the nitrogen atom to which they are attached

is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy; each $R^4$ is independently selected from (1-4C)alkyl, (1-4C)alkoxy, cyano, halogeno, hydroxyl and oxo;

n is 0, 1 or 2;

$R^5$ is hydrogen or (1-6C)alkyl;

$R^6$ is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-7)cycloalkyl, (1-6C)alkylsulfonyl, heterocyclyl, heteroaryl, (3-7)cycloalkyl(1-3C)alkyl, (3-7)heterocyclyl(1-3C)alkyl and heteroaryl(1-3C)alkyl,

and wherein any (1-3C)alkyl, (1-6C)alkyl, (3-7)cycloalkyl, heteroaryl or heterocyclyl group within $R^5$ or $R^6$ is optionally substituted on any available carbon atoms by 1, 2 or 3 substituents independently selected from halogeno, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by (1-4C)alkyl or (2-4C)alkanoyl, or $R^5$ and $R^6$ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy, and optionally substituted on any available ring nitrogen by a substituent selected from (1-4C)alkyl and (2-4C)alkanoyl provided the ring is not thereby quaternised,

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by $R^5$ and $R^6$ together with the nitrogen atom to which they are attached is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy;

provided that when the pyrrolidinyloxy group is linked to the 6-position of the quinazoline ring, m is 2 and substituents $R^1$ are both halogeno and attached to the 2- and 3-positions of the ring A, then $R^6$ is selected from (1-6C)alkyl substituted by 1, 2 or 3 substituents independently selected from halogeno, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy), (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-7)cycloalkyl, (1-6C)alkylsulfonyl, (3-7)heterocyclyl, heteroaryl, (3-7)cycloalkyl(1-6C)alkyl, (3-7)heterocyclyl(1-6C)alkyl and heteroaryl(1-6C)alkyl,

and wherein any (3-7)cycloalkyl, heteroaryl or (3-7)heterocyclyl group within $R^6$ is optionally substituted on any available carbon atoms by 1, 2 or 3 substituents independently selected from halogeno, hydroxy, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heteroaryl or heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by (1-4C)alkyl or (2-4C)alkanoyl, or $R^5$ and $R^6$ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which contains one or two nitrogen atoms as the only hetero atoms present in the ring and which is optionally substituted

on an available ring carbon atom by 1 or 2 substituents independently selected from hydroxy, carbamoyl, (1-4C)alkyl, and (1-3C)alkylenedioxy;

and wherein any 4, 5 or 6 membered heterocyclic ring formed by $R^5$ and $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by (1-4C)alkyl or (2-4C)alkanoyl;

or a pharmaceutically-acceptable salt thereof.

2. (Previously presented) A quinazoline derivative according to claim 1, wherein $R^5$ is hydrogen or (1-6C)alkyl and $R^6$ is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-7)cycloalkyl, (1-6C)alkylsulfonyl, heterocyclyl, heteroaryl, (3-7)cycloalkyl(1-3C)alkyl, (3-7)heterocyclyl(1-3C)alkyl and heteroaryl(1-3C)alkyl,

and wherein any (1-3C)alkyl, (1-6C)alkyl, (3-7)cycloalkyl, heteroaryl or heterocyclyl group within $R^5$ or $R^6$ is optionally substituted on any available carbon atoms by 1, 2 or 3 substituents independently selected from halogeno, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by (1-4C)alkyl or (2-4C)alkanoyl, or $R^5$ and $R^6$ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy, and optionally substituted on any available ring

nitrogen by a substituent selected from (1-4C)alkyl and (2-4C)alkanoyl provided the ring is not thereby quaternised,

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by $R^5$ and $R^6$ together with the nitrogen atom to which they are attached is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy;

provided that when the pyrrolidinyloxy group is linked to the 6-position of the quinazoline ring, m is 2 and substituents $R^1$ are both halogeno and attached to the 2- and 3-positions of the ring A, then $R^6$ is selected from (1-6C)alkoxy, (1-6C)alkylsulfonyl, (3-7)heterocyclyl (wherein the heterocyclyl is carbon linked), heteroaryl, (3-7)heterocyclyl(1-6C)alkyl wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety, and heteroaryl(1-6C)alkyl, (1-6C)alkyl substituted by 1, 2 or 3 substituents independently selected from (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino, oxo and a (1-6C)alkoxycarbonyl together with a hydroxy group,

and wherein any heteroaryl or (3-7)heterocyclyl group within $R^6$ is optionally substituted on any available carbon atoms by 1, 2 or 3 substituents independently selected from halogeno, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy, and wherein any heteroaryl or heterocyclyl group within R.sup.6 is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by (1-4C)alkyl or (2-4C)alkanoyl, or

$R^5$ and $R^6$ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which contains one or two nitrogen atoms as the only hetero atoms

present in the ring and which is substituted on an available ring carbon atom by 1 or 2 substituents independently selected from carbamoyl and (1-3C)alkylenedioxy.

3. (Previously presented) A quinazoline derivative according to claim 1, wherein $R^5$ is hydrogen, methyl, ethyl propyl, isopropyl or isobutyl and $R^6$ is selected from hydrogen, methyl, ethyl propyl, isopropyl, isobutyl, vinyl, isopropenyl, allyl, but-2-enyl ethynyl, 2-propynyl, butynyl, methoxy, ethoxy propoxy,isopropoxy, cyclopropyl, cyclopentyl, cyclohexyl, azetidinyl, oxazepanyl, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, tetrahydropyrimidinyl, tetrahydrothienyl, tetrahydrothiopyranyl, thiomorpholinyl, pyrazolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidyl, furanyl, pyrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl, azetidinylmethyl, oxazepanylmethyl, pyrrolinylmethyl, pyrrolidinylmethyl, morpholinylmethyl, tetrahydro-1,4-thiazinylmethyl, piperidinylmethyl, homopiperidinylmethyl, piperazinylmethyl, homopiperazinylmethyl, dihydropyridinylmethyl, tetrahydropyridinylmethyl, dihydropyrimidinylmethyl, tetrahydropyrimidinylmethyl, tetrahydrothienylmethyl, tetrahydrothiopyranylmethyl, thiomorpholinylmethyl, pyrazolylmethyl, thienylmethyl, oxazolylmethyl, isoxazolylmethyl, imidazolylmethyl, pyridinylmethyl, pyridazininylmethyl, pyrazinylmethyl, pyrimidylmethyl, furanylmethyl, pyrazolylmethyl, thiazolylmethyl, isothiazolylmethyl, thiadiazolylmethyl, 2-(azetidinyl)ethyl, 2-(oxazepanyl)ethyl, 2-(pyrrolinyl)ethyl, 2-(pyrrolidinyl)ethyl, 2-

(morpholinyl)ethyl, 2-(tetrahydro-1,4-thiazinyl)ethyl, 2-(piperidinyl)ethyl, 2-(homopiperidinyl)ethyl, 2-(piperazinyl)ethyl, 2-(homopiperazinyl)ethyl, 2-(dihydropyridinyl)ethyl, 2-(tetrahydropyridinyl)ethyl, 2-(dihydropyrimidinyl)ethyl, 2-(tetrahydropyrimidinyl)ethyl, 2-(tetrahydrothienyl)ethyl, 2-(tetrahydrothiopyranyl)ethyl, 2-(thiomorpholinyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thienyl)ethyl, 2-(oxazolyl)ethyl, 2-(isoxazolyl)ethyl, 2-(imidazolyl)ethyl, 2-(pyridinyl)ethyl, 2-(pyridazinyl)ethyl, 2-(pyrazinyl)ethyl, 2-(pyrimidyl)ethyl, 2-(furanyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thiazolyl)ethyl, 2-(isothiazolyl)ethyl and 2-(thiadiazolyl)ethyl,

and wherein any alkyl, cycloalkyl, heteroaryl or heterocyclyl group within $R^5$ or $R^6$ is optionally substituted on any available carbon atoms by 1 or 2 substituents independently selected from fluoro, chloro, bromo, hydroxymethyl, 2-hydroxyethyl, methoxycarbonyl ethoxycarbonyl, carbamoyl, acetamido, propionamido and hydroxy and/or optionally a substituent selected from oxo, cyano, methoxy and ethoxy, and wherein any heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by methyl, ethyl, acetyl or propionyl, or $R^5$ and $R^6$ together with the nitrogen atom to which they are attached form a azetidin-1-yl, pyrrolin-1-yl, pyrrolidin-1-yl, piperidino, morpholino or piperazino ring which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from fluoro, chloro, bromo, hydroxy, methyl, ethyl and propylenedioxy, and optionally substituted on any available ring nitrogen by a substituent selected from methyl, ethyl, acetyl and propionyl provided the ring is not thereby quaternised,

and wherein any alkyl or alkanoyl group present as a substituent on the ring formed by $R^5$ and $R^6$ together with the nitrogen atom to which they are attached is optionally substituted by 1 or 2 substituents independently selected from fluoro, chloro, bromo and hydroxy and/or optionally a substituent selected from methyl, ethyl, methoxy and ethoxy;

provided that when the pyrrolidinyloxy group is linked to the 6-position of the quinazoline ring, m is 2 and substituents $R^1$ are both halogeno and attached to the 2- and 3-positions of the ring A, then $R^6$ is selected from methoxy, ethoxy, propoxy, isopropoxy, substituted-methyl, substituted-ethyl, substituted-propyl, substituted-isopropyl, and substituted-isobutyl, wherein the substituted groups are substituted by 1 or 2 substituents independently selected from methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido, propionamido, oxo, a methoxycarbonyl group together with a hydroxy group, and an ethoxycarbonyl group together with a hydroxy group,

a carbon linked heterocyclyl group selected from azetidinyl, oxazepanyl, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydrofuranyl, tetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, tetrahydropyrimidinyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, thiomorpholinyl;

a heteroaryl group selected from pyrazolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl;

a (3-7)heterocyclyl(1-6C)alkyl group wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety selected from azetidinylmethyl, oxazepanylmethyl,

pyrrolinylmethyl, pyrrolidinylmethyl, morpholinylmethyl, tetrahydro-1,4-thiazinylmethyl, piperidinylmethyl, homopiperidinylmethyl, piperazinylmethyl, homopiperazinylmethyl, dihydropyridinylmethyl, tetrahydropyridinylmethyl, dihydropyrimidinylmethyl, tetrahydropyrimidinylmethyl, tetrahydrofuranylmethyl, tetrahydrothienylmethyl, tetrahydropyranylmethyl, tetrahydrothiopyranylmethyl, thiomorpholinylmethyl, 2-(azetidinyl)ethyl, 2-(oxazepanyl)ethyl, 2-(pyrrolinyl)ethyl, 2-(pyrrolidinyl)ethyl, 2-(morpholinyl)ethyl, 2-(tetrahydro-1,4-thiazinyl)ethyl, 2-(piperidinyl)ethyl, 2-(homopiperidinyl)ethyl, 2-(piperazinyl)ethyl, 2-(homopiperazinyl)ethyl, 2-(dihydropyridinyl)ethyl, 2-(tetrahydropyridinyl)ethyl, 2-(dihydropyrimidinyl)ethyl, 2-(tetrahydropyrimidinyl)ethyl, 2-(tetrahydrofuranyl)ethyl, 2-(tetrahydrothienyl)ethyl, 2-(tetrahydropyranyl)ethyl, 2-(tetrahydrothiopyranyl)ethyl, 2-(thiomorpholinyl)ethyl, a heteroaryl(1-6C)alkyl group selected from pyrazolylmethyl, thienylmethyl, oxazolylmethyl, isoxazolylmethyl, imidazolylmethyl, pyridinylmethyl, pyridazinylmethyl, pyrazinylmethyl, pyrimidylmethyl, furanylmethyl, pyrazolylmethyl, thiazolylmethyl, isothiazolylmethyl, thiadiazolylmethyl, 2-(pyrazolyl)ethyl, 2-(thienyl)ethyl, 2-(oxazolyl)ethyl, 2-(isoxazolyl)ethyl, 2-(imidazolyl)ethyl, 2-(pyridinyl)ethyl, 2-(pyridazinyl)ethyl, 2-(pyrazinyl)ethyl, 2-(pyrimidyl)ethyl, 2-(furanyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thiazolyl)ethyl, 2-(isothiazolyl)ethyl and 2-(thiadiazolyl)ethyl,

and wherein any heteroaryl or heterocyclyl group within $R^6$ is optionally substituted on any available carbon atoms by 1 or 2 substituents independently selected from fluoro, chloro, bromo, hydroxymethyl, 2-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido, propionamido and hydroxy and/or optionally a substituent selected from oxo, cyano, methoxy and ethoxy,

and wherein any heteroaryl or heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by methyl, ethyl, acetyl or propionyl;

or $R^5$ and $R^6$ together with the nitrogen atom to which they are attached form an azetidin-1-yl ring substituted carbamoyl or (1-3C)alkylenedioxy.

4. (Previously presented) A quinazoline derivative according to claim 1, wherein $R^5$ is hydrogen, methyl or ethyl and $R^6$ is selected from hydrogen, methyl, ethyl, propyl, isopropyl, isobutyl, vinyl, isoprop-2-enyl, allyl, but-2-enyl ethynyl, 2-prop-2-ynyl, but-3-ynyl, methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, thiomorpholinyl, 1,2,3,6-tetrahydropyridin-1-yl, pyrazolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidyl, furanyl, pyrazolyl, thiazolyl, isothiazolyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl, azetidinylmethyl, pyrrolinylmethyl, pyrrolidinylmethyl, morpholinylmethyl, piperidinylmethyl, piperazinylmethyl, tetrahydropyridinylmethyl, thiomorpholinylmethyl, pyrazolylmethyl, thienylmethyl, oxazolylmethyl, isoxazolylmethyl, imidazolylmethyl, pyridinylmethyl, pyridazinylmethyl, pyrazinylmethyl, pyrimidylmethyl, furanylmethyl, pyrazolylmethyl, thiazolylmethyl, isothiazolylmethyl, 2-(azetidinyl)ethyl2-(pyrrolinyl)ethyl, 2-(pyrrolidinyl)ethyl, 2-(morpholinyl)ethyl, 2-(piperidinyl)ethyl, 2-(piperazinyl)ethyl, 2-(tetrahydropyridinyl)ethyl, 2-(thiomorpholinyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thienyl)ethyl, 2-(oxazolyl)ethyl, 2-(isoxazolyl)ethyl, 2-(imidazolyl)ethyl, 2-(pyridinyl)ethyl, 2-(pyridazinyl)ethyl, 2-(pyrazinyl)ethyl, 2-

(pyrimidyl)ethyl, 2-(furanyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thiazolyl)ethyl and 2-(isothiazolyl)ethyl,

and wherein any alkyl, cycloalkyl, heteroaryl or heterocyclyl group within $R^5$ or $R^6$ is optionally substituted on any available carbon atoms by 1 or 2 substituents independently selected from fluoro, chloro, bromo, hydroxymethyl, 2-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido and hydroxy and/or optionally a substituent selected from oxo, cyano, methoxy, and ethoxy,

and wherein any heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by methyl, ethyl, acetyl or propionyl, or $R^5$ and $R^6$ together with the nitrogen atom to which they are attached form a azetidin-1-yl, pyrrolin-1-yl, pyrrolidin-1-yl, piperidino, morpholino or piperazino ring which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from fluoro, chloro, hydroxy, methyl, ethyl and propylenedioxy, and optionally substituted on any available ring nitrogen by a substituent selected from methyl, ethyl, acetyl and propionyl provided the ring is not thereby quaternised, and wherein any alkyl or alkanoyl group present as a substituent on the ring formed by $R^5$ and $R^6$ together with the nitrogen atom to which they are attached is optionally substituted by 1 or 2 substituents independently selected from fluoro, chloro and hydroxy and/or optionally a substituent selected from methyl, ethyl methoxy and ethoxy;

provided that when the pyrrolidinyloxy group is linked to the 6-position of the quinazoline ring, m is 2 and substituents $R^1$ are both halogeno and attached to the 2- and 3-positions of the ring A, then $R^6$ is selected from methoxy, ethoxy, substituted-

methyl, substituted-ethyl substituted-propyl, substituted-isopropyl, substituted-isobutyl, (wherein the substituted groups are substituted by 1 or 2 substituents independently selected from methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido and oxo or a methoxycarbonyl group together with a hydroxy group,

a carbon linked heterocyclyl group selected from azetidinyl, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyridinyl, tetrahydropyranyl, thiomorpholinyl,

a heteroaryl group selected from pyrazolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidyl, furanyl, pyrazolyl, thiazolyl, isothiazolyl,

a (3-7)heterocyclyl(1-6C)alkyl group wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety selected from azetidinylmethyl, pyrrolinylmethyl, pyrrolidinylmethyl, morpholinylmethyl, piperidinylmethyl, piperazinylmethyl, tetrahydrofuranylmethyl, tetrahydropyranylmethyl, tetrahydropyridinylmethyl, thiomorpholinylmethyl, 2-(azetidinyl)ethyl, 2-(pyrrolinyl)ethyl, 2-(pyrrolidinyl)ethyl, 2-(morpholinyl)ethyl, 2-(piperidinyl)ethyl, 2-(piperazinyl)ethyl, 2-(tetrahydrofuranyl)ethyl, 2-(tetrahydropyranyl)methyl, 2-(tetrahydropyridinyl)ethyl, 2-(thiomorpholinyl)ethyl, a heteroaryl(1-6C)alkyl group selected from pyrazolylmethyl, thienylmethyl, oxazolylmethyl, isoxazolylmethyl, imidazolylmethyl, pyridinylmethyl, pyridazinylmethyl, pyrazinylmethyl, pyrimidylmethyl, furanylmethyl, pyrazolylmethyl, thiazolylmethyl, isothiazolylmethyl, 2-(pyrazolyl)ethyl, 2-(thienyl)ethyl, 2-(oxazolyl)ethyl, 2-(isoxazolyl)ethyl, 2-(imidazolyl)ethyl, 2-(pyridinyl)ethyl, 2-(pyridazinyl)ethyl, 2-

(pyrazinyl)ethyl, 2-(pyrimidyl)ethyl, 2-(furanyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thiazolyl)ethyl and 2-(isothiazolyl)ethyl,

and wherein any heteroaryl or heterocyclyl group within $R^6$ is optionally substituted on any available carbon atoms by 1 or 2 substituents independently selected from fluoro, chloro, bromo, hydroxymethyl, 2-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido and hydroxy and/or optionally a substituent selected from oxo, cyano, methoxy and ethoxy,

and wherein any heteroaryl or heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by methyl, ethyl, acetyl or propionyl;

or $R^5$ and $R^6$ together with the nitrogen atom to which they are attached form an azetidin-1-yl ring substituted by a carbamoyl group.

5. (Previously presented) A quinazoline derivative according to claim 1, wherein $R^5$ is hydrogen or methyl and $R^6$ is selected from hydrogen, methyl, ethyl, propyl, isopropyl, vinyl, isoprop-2-enyl, allyl, but-2-enyl ethynyl, 2-propynyl, but-3-ynyl, methoxy, cyclopropyl, cyclopentyl, 1-(hydroxymethyl)cyclopentyl, cyclohexyl, 4-hydroxycyclohexyl, cyclopropylmethyl, cyclopentylmethyl, methoxymethyl, 2-(methoxy)ethyl, 2-(ethoxy)ethyl, carbamoylmethyl, 2-(acetyl)ethyl, cyanomethyl, 2-(cyano)ethyl, 2,3-dihydroxypropyl, 2-(hydroxyl)-1,1-dimethylethyl, 2,2,2-trifluoroethyl, 1-(ethoxycarbonyl)-2-hydroxyethyl, 2-acetamido)ethyl, tetrahydrofuran-2-ylmethyl, imidazol-2-ylmethyl, 1-methylpyrazol-5-yl, 1-methylpyrazol-5-yl, 3-methylpyrazol-5-yl, imidazol-1-ylmethyl, 2-(imidazol-1-yl)ethyl, furan-2-ylmethyl,2-(furan-2-yl)ethyl, 5-

methylisoxazol-3-ylmethyl, thien-3yl, morpholino, piperidin-4-yl, 1-methylpiperidin-4-yl, tetrahydro-2H-pyran-4-yl and 3-oxotetrahydrofuran-4-yl,

or $R^5$ and $R^2$ together with the nitrogen atom to which they are attached form a 3-hydroxyazetidin-1-yl, 2-carbamoylazetidin-1-yl, pyrrolin-1-yl, pyrrolidin-1-yl, 3-hydroxy, pyrrolidin-1-yl, piperidino, morpholino or piperazino group;

provided that when the pyrrolidinyloxy group is linked to the 6-position of the quinazoline ring, m is 2 and substituents $R^1$ are both halogeno and attached to the 2- and 3-positions of the ring A, then $R^6$ is selected from methoxy, carbamoylmethyl, 2-(hydroxy)-1-(methoxycarbonyl)ethyl, 1-(ethoxycarbonyl)-2-hydroxyethyl, 2-(acetamido)ethyl, piperidin-4-yl, 1-methylpiperidin-4yl, tetrahydropyran-4-yl, 4-hydroxytetrahydrofuran-3-yl, 3-oxotetrahydrofuran-4-yl, 1-methylpyrazol-5-yl, thien-3yl, 3-methylpyrazol-5-yl, tetrahydrofuran-2-ylmethyl, tetrahydropyran-4-ylmethyl, furan-2-ylmethyl, 2-(furan-2-yl)ethyl, imidazol-1-ylmethyl, imidazol-2-ylmethyl, imidazol-2-ylmethyl, 2-(imidazol-1-yl)ethyl, 2-(imidazol-4-yl)ethyl and 5-methylisoxazol-3-ylmethyl or $R^5$ and $R^6$ together with the nitrogen atom to which they are attached form an azetidinyl substituted in the 2 position by a carbamoyl group.

6. (Previously presented) A quinazoline derivative according to claim 1, wherein $R^5$ is hydrogen or (1-6C)alkyl and $R^6$ is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-7)cycloalkyl, (1-6C)alkylsulfonyl, heterocyclyl, heteroaryl, (3-7)cycloalkyl(1-3C)alkyl, (3-7)heterocyclyl(1-3C)alkyl and heteroaryl(1-3C)alkyl, and wherein any (1-3C)alkyl, (1-6C)alkyl, (3-7)cycloalkyl, heteroaryl or heterocyclyl group within $R^5$ or $R^6$ is optionally substituted on any available carbon atoms by 1, 2 or 3

substituents independently selected from halogeno, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by (1-4C)alkyl or (2-4C)alkanoyl, or $R^5$ and $R^6$ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy, and optionally substituted on any available ring nitrogen by a substituent selected from (1-4C)alkyl and (2-4C)alkanoyl provided the ring is not thereby quaternised,

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by $R^5$ and $R^6$ together with the nitrogen atom to which they are attached is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy;

provided that when the pyrrolidinyloxy group is linked to the 6-position of the quinazoline ring, m is 2 and substituents $R^1$ are both halogeno and attached to the 2- and 3-positions of the ring A, then $R^6$ is selected from (3-7)heterocyclyl wherein heterocyclyl is carbon linked, heteroaryl, (3-7)heterocyclyl(1-6C)alkyl wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety and heteroaryl(1-6C)alkyl,

and wherein any heteroaryl or (3-7)heterocyclyl group within $R^6$ is optionally substituted on any available carbon atoms by 1, 2 or 3 substituents independently selected from halogeno, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl,

carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heteroaryl or heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by (1-4C)alkyl or (2-4C)alkanoyl.

7. (Previously presented) A quinazoline derivative according to claim 1, wherein m is 0, 1, 2 or 3 and $R^1$ is independently selected from halogeno, cyano, nitro, hydroxy, trifluoromethyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, ureido, N-(1-6C)alkylureido, N,N-di-[(1-6C)alkyl]ureido, --$NR^aR^b$, --$SO_2NR^aR^b$ and a group of the formula
--$CONR^aR^b$ wherein $R^a$ and $R^b$ are as hereinabove defined;

or, when two $R^1$ groups are attached to adjacent carbon atoms, they may, together with the carbon atoms to which they are attached, form a pyrrole ring, wherein the pyrrole ring is optionally substituted by 1 or 2 substituents independently selected from (1-6C)alkyl, halogeno, cyano, nitro, hydroxy, amino, carbamoyl, sulfamoyl and trifluoromethyl;

or, when two $R^1$ groups are attached to adjacent carbon atoms, they may, together form a (1-3C)alkylenedioxy group.

8. (Previously presented) A quinazoline derivative according to claim 7, wherein m is 0, 1 or 2 and $R^1$ is independently selected from fluoro, chloro, cyano, trifluoromethyl, methyl, methoxy, methylthio, isobutylthio, sulfamoyl, and a group of the formula

--$CONR^aR^b$ wherein $R^a$ is hydrogen or methyl and $R^b$ selected from hydrogen, methyl, ethyl, isobutyl, furanyl, cyclopentyl and cyclohexyl,

wherein any alkyl, (3-7)cycloalkyl, heteroaryl in $R^a$ and $R^b$ are optionally substituted by 1 or 2 substituents selected from hydroxy and methoxy;

or $R^a$ and $R^b$ together with the nitrogen atom to which they are attached form a 1,2,3,6-tetrahydropyridin-1-yl, pyrrolidin-1-yl, piperidino, piperazin-1-yl or morpholino ring, which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from hydroxyl and optionally substituted on any available ring nitrogen by a substituent selected from methyl and acetyl provided the ring is not thereby quaternised,

or, when two $R^1$ groups are attached to adjacent carbon atoms, they may, together with the carbon atoms to which they are attached, form a pyrrole ring, wherein the pyrrole ring is optionally substituted by 1 or 2 substituents independently selected from hydroxy; or, when two $R^1$ groups are attached to adjacent carbon atoms, they may, together form a (1-3C)alkylenedioxy group.

9. (Previously presented) A quinazoline derivative according to claim 7, wherein m is 2 and $R^a$ is positioned in the 2- and 3-positions of ring A and $R^1$ is independently selected from fluoro and chloro.

10. (Previously presented) A quinazoline derivative according to claim 9, wherein ring A is phenyl or pyrid-3-yl.

11. (Previously presented) A quinazoline derivative according to claim 10, wherein ring A is phenyl.

12. (Previously presented) A quinazoline derivative according to claim 1, wherein $R^2$ is selected from hydrogen, (1-6C)alkyl and a group of formula $R^7O$--, wherein $R^7$ is (1-6C)alkyl optionally substituted by 1 or 2 substituents independently selected from hydroxy and a group of formula $R^8O$-- wherein $R^8$ is (1-3C)alkyl.

13. (Previously presented) A quinazoline derivative according to claim 12, wherein $R^2$ is selected from hydrogen, methyl, ethyl and a group of formula $R^7O$--, wherein $R^7$ is methyl or ethyl.

14. (Previously presented) A quinazoline derivative according to claim 13, wherein $R^2$ is methoxy.

15. (Previously presented) A quinazoline derivative according to claim 13, wherein $R^2$ is hydrogen.

16. (Previously presented) A quinazoline derivative according to claim 1, wherein $R^2$ is in the 6-position and the substituted-pyrrolidinyloxy group is in the 7-position of the quinazoline ring.

17. (Previously presented) A quinazoline derivative according to claim 1, wherein $R^2$

is in the 7-position and the substituted-pyrrolidinyloxy group is in the 6-position of the quinazoline ring.

18. (Previously presented) A quinazoline derivative according to claim 1, wherein $R^3$ is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-3C)alkyl (2-6C)alkanoyl;

and wherein any (1-6C)alkyl or (2-6C)alkanoyl group within $R^3$ is optionally substituted by 1 or 2 substituents independently selected from halogeno, hydroxy and (1-6C)alkyl and/or optionally a substituent selected from cyano, nitro, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy and $NR^cR^d$, wherein $R^c$ is hydrogen or (1-4C)alkyl and $R^d$ is hydrogen or (1-4C)alkyl.

19. (Previously presented) A quinazoline derivative according to claim 18, wherein $R^3$ is methyl.

20. (Previously presented) A quinazoline derivative according to claim 1, wherein n is 0, 1 or 2 and $R^4$ is independently selected from methyl, ethyl, methoxy, ethoxy, hydroxyl and oxo.

21. (Previously presented) A quinazoline derivative according to claim 20, wherein n is 0.

22. (Previously presented) A quinazoline derivative according to claim 1, wherein

the --$CONR^5R^6$ group is in the 2-position of the pyrrolidine ring.

23. (Previously presented) A quinazoline derivative according to claim 1, wherein the substituted-quinazolinyloxy group is in the 3-position of the pyrrolidine ring.

24. (Previously presented) A quinazoline derivative according to claim 1 having a structural sub-formula A2:




(A2)

wherein:

m is 2 and $R^1$ is 2-fluoro and 3-chloro;

$R^2$ is methoxy;

$R^3$ is methyl;

n is 0; and

$R^5$ is hydrogen or (1-6C)alkyl and $R^6$ is selected from (1-6C)alkoxy, (1-6C)alkylsulfonyl, (3-7)heterocyclyl (wherein the heterocyclyl is carbon linked), heteroaryl, (3-7)heterocyclyl(1-6C)alkyl wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety, heteroaryl(1-6C)alkyl, (1-6C)alkyl substituted by 1, 2 or 3

substituents independently selected from (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino, oxo, and a (1-6C)alkoxycarbonyl together with a hydroxy group,

and wherein any heteroaryl or (3-7)heterocyclyl group within $R^6$ is optionally substituted on any available carbon atoms by 1, 2 or 3 substituents independently selected from halogeno, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy, and wherein any heteroaryl or heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by (1-4C)alkyl or (2-4C)alkanoyl,

or $R^5$ and $R^6$ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which contains one or two nitrogen atoms as the only heteroatoms present in the ring and which is optionally and which is substituted on an available ring carbon atom by 1 or 2 substituents independently selected from carbamoyl and (1-3C)alkylenedioxy.

25. (Previously presented) A quinazoline derivative according to claim 24, wherein $R^6$ is selected from (3-7)heterocyclyl wherein the heterocyclyl is carbon linked, heteroaryl, (3-7)heterocyclyl(1-6C)alkyl wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety, and heteroaryl(1-6C)alkyl,

and wherein any heteroaryl or (3-7)heterocyclyl group within $R^6$ is optionally substituted on any available carbon atoms by 1, 2 or 3 substituents independently selected from halogeno, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl,

carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heteroaryl or heterocyclyl group within $R^6$ is optionally substituted on any available ring nitrogen provided the ring is not thereby quaternised by (1-4C)alkyl or (2-4C)alkanoyl.

26. (Original) A quinazoline derivative selected from one or more of the following:
(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]quinazolin-7-yl}oxy)-N,N,1-tri- methyl-L-prolinamide;
(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]quinazolin-7-yl}oxy)-1-methyl-L-prolinamide;
(4S)-4-({4-[(4-cyano-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;
(4S)-4-({4-[(3-chloro-4-cyanophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;
(4S)-4-[(4-{[3-chloro-4-(trifluoromethyl)phenyl]amino}-7-methoxyquinazoli-n-6-yl)oxy]-N,N,1-trimethyl-D-prolinamide;
(4S)-4-({4-[(5-chloropyridin-3-yl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;
(4S)-4-({4-[(2-fluoro-4-methylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;
(4S)-4-({4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(2-fluoro-4-hydroxyphenyl)amino]-7-methoxyquinazolin-6-yl}oxy- )-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(2,4-difluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,-1-trimethyl-D-prolinamide;

(4S)-4-({4-[(2,5-difluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,-1-trimethyl-D-prolinamide;

(4S)-4-({4-[(5-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(4chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(5-chloro-2-hydroxyphenyl)amino]-7-methoxyquinazolin-6-yl}oxy- )-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-4-methoxyphenyl)amino]-7-methoxyquinazolin-6-yl}oxy- )-N,N,1-trimethyl-D-prolinamide;

(4S)-4-[(4-{[2-(aminosulfonyl)-5-chlorophenyl]amino}-7-methoxyquinazolin-- 6-yl)oxy]-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({7-methoxy-4-[(2,3,4-trifluorophenyl)amino]quinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-[(4-{[2-fluoro-5-(trifluoromethyl)phenyl]amino}-7-methoxyquinazoli-n-6-yl)oxy]-N,N,1-trimethyl-D-prolinamide;

(4S)-4-[(4-{[2-fluoro-3-(trifluoromethyl)phenyl]amino}-7-methoxyquinazoli-n-6-yl)oxy]-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-methoxyphenyl)amino]-7-methoxyquinazolin-6-yl}oxy- )-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-methylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-4-hydroxyphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-cyanophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-tri-methyl-D-prolinamide;

(4S)-4-{[4-(1H-indol-5-ylamino)-7-methoxyquinazolin-6-yl]oxy}-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-1H-indol-5-yl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopropyl-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyclopropylmethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxyethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopentyl-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopentylmethyl-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxyethyl)-N,1-dimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-methoxy-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclohexyl-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(tetrahydro-2H-pyran-4-yl)-D-prolinamide; and

(4S)-4-({4-[(3-chloro-4-fluorophenyl)amino]-6-methoxyquinazolin-7-yl}oxy)-N,N,1-trimethyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(3-furylmethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-furylmethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-[(5-methylisoxazol-3-yl)methyl]-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[2-(1H-imidazol-1-yl)ethyl]-1-methyl-D-prolinamide;

(2S)-1-[(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-D-prolyl]azetidine-2-carboxamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(2R)-2,3-dihydroxypropyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(1-methyl-1H-pyrazol-5-yl)-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-3-thienyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(3-methyl-1H-pyrazol-5-yl)-D-prolinamide;

methyl(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-y- l}oxy)-1-methyl-D-prolyl-L-serinate;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-D-prolylglycinamide;

(4S)-N-[2-(acetylamino)ethyl]-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-m-ethoxyquinazolin-6-yl}oxy)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[1-(hydroxymethyl)cyclopentyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[2-(1H-imidazol-4-yl)ethyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxy-1-methylethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(2,2,2-trifluoroethyl)-D-prolinamide;

(4S)-N-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-D-prolinamide (4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-ethoxyethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(4-hydroxycyclohexyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(2-methylprop-2-en-1-yl)-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1S)-1-(hydroxymethyl)propyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(2S)-2,3-dihydroxypropyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(1H-imidazol-2-ylmethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[2-(2-furyl)ethyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1S)-2-hydroxy-1-methylethyl]-1-methyl-D-prolinamide;

(4S)-4-({4[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1R)-2-hydroxy-1-methylethyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(2R)-2-hydroxypropyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(2S)-2-hydroxypropyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-[(2R)-tetrahydrofuran-2-ylmethyl]-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-D-prolinamide N-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[(3S,5R)-1-methyl-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl}oxy}quinazolin-4-amine;

N-(3-chloro-2-fluorophenyl)-7-methoxy-6-({(3S,5R)-1-methyl-S-[(4methylpiperazin-1-yl)carbonyl}pyrrolidin-3-yl)oxy)quinazolin-4-amine 6-{[(3S,5R)-5-(azetidin-1-ylcarbonyl)-1-methylpyrrolidin-3-yl]oxy}-N-(3-c- hloro-2-fluorophenyl)-7-methoxyquinazolin-4-amine;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyanomethyl)-N,1-dimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyanomethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,1-dimethyl-N-[(2S)-2-pyrrolidin-1-ylpropyl]-D-prolinamide; (4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1R)-2-hydroxy-1-methylethyl]-N,1-dimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,1-dimethyl-N-(1-methylpiperidin-4yl)-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,1-dimethyl-N-(tetrahydro-2H-pyran-4-yl)-D-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7methoxyquinazolin-6-yl}oxy)-1-methyl-N-prop-2-yn-1-yl-L-prolinamide;

1-[[(2S,4R)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl]carbonyl]-3-pyrroline;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyanomethyl)-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-cyanoethyl)-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyanomethyl)-N,1-dimethyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxyethyl)-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopropyl-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopentyl-1-methyl-L-prolinamide;

N-(3-chloro-2-fluorophenyl)-7-methoxy-6-({(3R,5S)-1-methyl-5-[(methylpiperazin-1-yl)carbonyl]pyrrolidin-3-yl}oxy)quinazolin-4-amine;

(3S)-1-[(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-L-prolyl]pyrrolidin-3-ol (4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyclopropylmethyl)-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclohexyl-N,1-dimethyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(tetrahydro-2H-pyran-4-yl)-L-prolinamide;

N-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[(3R,5S)-1-methyl-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl]oxy}quinazolin-4-amine;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-hydroxyethyl)-N,1-dimethyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[2-(dimethylamino)ethyl]-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,1-dimethyl-N-(1-methylpiperidin-4-yl)-L-prolinamide;

6-({(3R,5S)-5-[(4-acetylpiperazin-1-yl)carbonyl]-1-methylpyrrolidin-3-yl}oxy)-N-(3-chloro-2-fluorophenyl)-7-methoxyquinazolin-4-amine;

1-[(4R)-4-({4[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6yl}oxy- )-1-methyl-L-prolyl]piperidin-4-ol;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxyethyl)-N,1-dimethyl-L-prolinamide; (4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl)}oxy)-N-cyclohexyl-1-methyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopropyl-1-methyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxyethyl)-1-methyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclohexyl-N,1-dimethyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(tetrahydro-2H-pyran-4-yl)-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxyethyl)-N,1-dimethyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,1-dimethyl-N-(1-methylpiperidin-4-yl)-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopentyl-1-methyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-methoxy-1-methyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyclopropylmethyl)-1-methyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclohexyl-1-methyl-L-prolinamide;
and pharmaceutically-acceptable salts thereof.

27. (Original) (4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]quinazolin-7-yl}oxy)-1-methyl-L-prolinamide trifluoroacetic acid salt.

28. (Previously presented) A pharmaceutical composition which comprises a quinazoline derivative of Formula I, or a pharmaceutically-acceptable salt thereof, as defined in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

29. (Previously presented) A quinazoline derivative of the Formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, for use as a medicament.

30. (Cancelled)

31. (Currently Amended) A method for producing an anti-proliferative effect in a warm-blooded animal in need of such treatment, which comprises administering to, said animal a quinazoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1,

wherein said anti-proliferative effect treats a cancer chosen from leukaemia, multiple myeloma, lymphoma, bile duct, bone, bladder, brain/CNS, breast, colorectal,

endometrial, gastric, head, neck, hepatic, lung, neuronal, oesophageal, ovarian, pancreatic, prostate, renal, skin, testicular, thyroid, uterine, and vulval cancers.

32. (Previously presented) A process for the preparation of a quinazoline derivative of the Formula I as defined in claim 1 which is selected from one of the following:

**Process (a)** reacting a compound of the Formula II:




(II)

wherein $R^1$, $R^2$, A, m and n have any of the meanings defined in claim 1, except that any functional group is protected if necessary,

with a compound of the Formula III in the presence of a suitable base:




(III)

wherein $R^3$, $R^4$, $R^5$, $R^6$ and p have any of the meanings defined in claim 1, except that any functional group is protected if necessary and Lg is a displaceable group, and

whereafter any protecting group that is present is removed;

**Process (b)** modifying a substituent in, or introducing a substituent into, another quinazoline derivative of Formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1, except that any functional group is protected if necessary, and

whereafter any protecting group that is present is removed;

**Process (c)** the removal of a protecting group from a quinazoline derivative of Formula I, or a pharmaceutically acceptable salt thereof, as claimed in claim 1;

**Process (d)** reacting a compound of the Formula II as defined in reference to process (a) above with a compound of the Formula III as defined in reference to process (a) above, except Lg is OH, under Mitsunobu conditions, and

whereafter any protecting group that is present is removed;

**Process (e)** For the preparation of those compounds of the Formula I defined in claim 1 wherein $R^4$ is a hydroxy group, by the cleavage of a quinazoline derivative of the Formula I wherein $R^4$ is a (1-4C)alkoxy group;

**Process (f)** For the preparation of those compounds of the Formula I defined in claim 1 wherein $R^4$ is (1-4C)alkoxy, by the reaction of a compound of the Formula IV:




(IV)

with a compound of the formula (1-4C)alkyl-Lg in the presence of a base, wherein Lg is a displaceable group, and

whereafter any protecting group that is present is removed;

**Process (g)** For the preparation of those compounds of the Formula I defined in claim 1 wherein $R^1$, $R^2$, $R^4$ or $R^5$ contain a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a (1-6C)alkylamino or substituted (1-6C)alkylamino group, said process comprising the alkylation of a quinazoline derivative of the Formula I wherein $R^1$, $R^2$, $R^4$ or $R^5$ contain a hydroxy group or a primary or secondary amino group as appropriate;

**Process (h)** reacting a compound of the formula (V) or reactive derivative thereof with a compound of the formula $HNR^5R^6$ or a suitable salt thereof in the presence of a base and in an inert solvent;

**Process (i)** reacting a compound of the formula VI: wherein $R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^6$ n and p, have any of the meanings defined in claim 1, except that any functional group is protected if necessary, and Lg is a displaceable group as defined in reference to Process (a) above,

with an aniline of the formula VII in the presence of a suitable acid:




(VII)

wherein $R^1$ and m have any of the meanings defined defined in claim 1, except that any functional group is protected if necessary,

**Process (j)** Forming the group --CON($R^5$)$R^6$ by reacting to the corresponding carboxy compound, wherein any functional groups are protected if necessary, with a primary or secondary amine or a heterocyclic group containing an NH group; and

whereafter any protecting group that is present is removed.

33. (Cancelled)

34. (Cancelled)